Empagliflozin 25 mg Tablet
Empagliflozin 25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
MFDS item code 202102111 · Approved 2021.03.05
Improvement of glycemic control in adults with type 2 diabetes
This medication is used as a treatment to help control blood glucose levels in adults with type 2 diabetes, acting as an adjunct to dietary management and exercise. It can be used as monotherapy but is often administered in combination with metformin for patients who have not previously been treated with diabetes medications or find it difficult to control blood glucose levels alone. Additionally, it can be added when sufficient blood glucose control is not achieved with metformin alone. It can also be used alongside pioglitazone, sulfonylureas, insulin, or the DPP-4 inhibitor linagliptin when blood glucose control is inadequate. Special caution is needed for patients with type 2 diabetes who have cardiovascular diseases, and consulting related specialist information is advisable. This medication is used to improve blood glucose control in patients with type 2 diabetes.
The recommended dose of this medicine is 10 mg once daily, whether used as monotherapy or as add-on combination therapy with other glucose-lowering agents, such as insulin. If 10 mg of this medicine is well tolerated and additional glycemic control is needed, the dose may be increased to 25 mg once daily. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia. This medicine may be taken with or without food. Swallow the tablet whole. If you miss a dose, take it as soon as you remember. Do not take double the dose in one day. No dose adjustment is necessary in patients with mild renal impairment. Treatment with this medicine should not be initiated in patients with an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73m2 [or CrCl < 60 ml/min]. In patients who tolerate this medicine well and whose glomerular filtration rate remains < 60ml/min/1.73m2 [or CrCl < 60 ml/min], the dose should be adjusted to or maintained at 10 mg once daily. This medicine should be discontinued if the glomerular filtration rate decreases to < 45 ml/min/1.73m2 [or CrCl < 45 ml/min]. Do not use this medicine in patients with end-stage renal disease (ESRD) or those on dialysis, because efficacy is not expected. No dose adjustment is necessary in patients with mild or moderate hepatic impairment. Use of this medicine is not recommended in patients with severe hepatic impairment, as it has not been studied in this population. No dose adjustment based on age is necessary. Renal function and the risk of volume depletion should be considered in patients aged 75 years or older. Initiation of treatment with this medicine is not recommended in patients aged 85 years or older because clinical experience is limited.
This medication should not be administered to certain patients. First, individuals allergic to the active ingredient or any of the excipients should not take this medication. It is also not suitable for patients with type 1 diabetes or diabetic ketoacidosis. Patients with significantly reduced kidney function, with a glomerular filtration rate (GFR) of less than 30 mL/min/1.73m2, those with end-stage renal disease, or patients undergoing dialysis should also not use this medication. Furthermore, since this medication contains lactose, individuals with lactose intolerance, galactose intolerance, or inherited lactase deficiency should not take it. Caution is advised when using this medication in patients with slightly reduced kidney function. In particular, it is advised not to initiate this medication in patients with a GFR of less than 60 mL/min/1.73m2, and if they are currently taking it, the dosage may need to be reduced or discontinued. In patients with end-stage renal disease or those on dialysis, the efficacy of this medication is not expected, thus it should not be used. Patients with heart failure, particularly those with mild to moderate conditions, should use this medication cautiously, and it is not recommended for patients with severe heart failure. When used in combination with insulin or sulfonylureas, there is a risk of hypoglycemia, hence caution is needed and the dosages of these medications may need to be reduced. Possible side effects while taking this medication include hypoglycemia, urinary tract infections, genital infections, increased urination, decreased fluid volume, etc. Particularly, hypoglycemia may occur more frequently when combined with insulin or sulfonylureas, so vigilance is advised. Additionally, rare but serious adverse reactions such as ketoacidosis, pyelonephritis, and perineal necrosis have been reported, so immediate consultation with healthcare professionals is necessary upon the appearance of symptoms. This medication can affect the body’s fluid status, so elderly individuals, those with hypotension, and patients with cardiovascular diseases should be especially cautious. Pregnant women are advised not to take this medication, and it should be discontinued if pregnancy is confirmed. Breastfeeding women should also discontinue breastfeeding while on this medication. Its safety and efficacy have not been established in children under 18 years of age, thus it should not be used in this population. No specific toxic symptoms have been reported in cases of overdose, however, appropriate treatment is necessary depending on clinical conditions. This medication should be kept out of the reach of children, and it should not be transferred to other containers. Caution is required when driving or operating machinery due to the risk of hypoglycemia, especially when taken with insulin or other hypoglycemic agents. When monitoring blood glucose levels while taking this medication, the 1,5-AG test may be unreliable, so other methods are recommended. Finally, regular kidney function tests should be conducted while on this medication, and if symptoms of infection or abnormal signs appear, immediate consultation with healthcare professionals is necessary.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent exposure to air and moisture. It is best to maintain storage temperatures between 1 and 30 degrees Celsius at room temperature.
Light yellow, biconvex oval film-coated tablet
10 tablets/box (10 tablets/PTP x 1), 30 tablets/box (10 tablets/PTP x 3), 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Boehringer Ingelheim Korea Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Donggu Bio Pharmaceutical Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Korea Prime Pharmaceuticals Co., Ltd.

Empagliflozin 10mg
Tablet · Prescription medication
Korea Prime Pharmaceutical Co., Ltd.

Empagliflozin 25mg
Tablet · Prescription medication
Kips Biopharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.